Lyell Immunopharma: Differentiated CAR-T Durability and Second-Line LBCL Opportunity Underpin Buy Rating and $45 Target

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Lyell Immunopharma and keeping the price target at $45.00.

Mitchell Kapoor has given his Buy rating due to a combination of factors tied to Lyell’s differentiated CAR-T profile and expanding oncology footprint. He highlights the Phase 3 PiNACLE-H2H trial, which directly pits ronde-cel against approved CAR-Ts in second-line LBCL and reflects strong internal conviction in Lyell’s durability advantage, already demonstrated by leading long-term progression-free survival in later-line patients.

Mitchell Kapoor’s rating is based on the view that second-line use is a major value catalyst, supported by robust response rates in a particularly high-risk population and the potential for durable complete responses to drive rapid physician adoption. He also points to promising colorectal cancer data with LYL273, a rich 2026 catalyst calendar, a solid cash position with no debt, and a DCF analysis that indicates attractive upside despite execution and market risks, all of which support maintaining a Buy and a $45 price target.

Kapoor covers the Healthcare sector, focusing on stocks such as Halozyme, Legend Biotech, and Sarepta Therapeutics. According to TipRanks, Kapoor has an average return of 7.5% and a 40.63% success rate on recommended stocks.